Explain this page
Arphra AIPlain-English read on Arcus Biosciences, Inc.’s valuation06-09today
- Arcus Biosciences, Inc. (RCUS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript11d
- Arcus Biosciences Announces New Employment Inducement Grants11d
- Arcus Biosciences Announces New Employment Inducement Grants11d
- Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer18d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $31.00 (+27.52%)
Candlestick · 1Y
Open in chart workstation →RCUS
24.31+12.23%H 26.15L 18.52MA50 23.20MA200 —Avg vol 1.1M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.79% | -0.12% | +1.84% | +12.34% | +10.60% | +2.01% | +181.69% | +28.56% | +3.40% | +43.00% | +43.00% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$23.80
Bid
$18.34
100 sh
Ask
$26.00
3 sh
Spread
$7.660
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Arcus Biosciences, Inc. (RCUS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.com·Jun 09, 2026
- Arcus Biosciences Announces New Employment Inducement Grantsbusinesswire.com·Jun 09, 2026
- Arcus Biosciences Announces New Employment Inducement Grantsbusinesswire.com·Jun 09, 2026
- Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancerbusinesswire.com·Jun 03, 2026
- Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancerbusinesswire.com·Jun 03, 2026
Peers
No peer list available for RCUS.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|